C-QIP boosts secondary prevention delivery in Indian cardiovascular clinics
Chronic cardiovascular disease care often fails at the point where guidelines should become routine practice. In a pragmatic feasibility trial across four hospitals in India, a multicomponent collaborative quality improvement strategy translated those guidelines into more reliable outpatient care, especially for people with ischemic heart disease and ischemic stroke.
The intervention combined electronic decision support for providers, care coordination by non-physician staff, patient education, text-message reminders, and audit-feedback. Each component targeted a different failure point in chronic disease management: prescribing inertia, fragmented follow-up, limited patient understanding, and the common drift away from long-term preventive therapy once the acute event is over. In a setting where secondary prevention frequently stalls, the bundle was designed to make guideline-directed care harder to miss and easier to sustain.
The trial enrolled 410 adults with ischemic heart disease, ischemic stroke, or heart failure and randomized them 1:1 to the C-QIP strategy or usual care. Median follow-up reached 15 months, long enough to test whether the workflow could survive the realities of routine outpatient practice rather than a short-lived pilot. Retention remained high in both groups, with 192 of 206 participants in the intervention arm and 187 of 204 in the usual-care arm completing the study.
Care processes held up in the real world
The implementation signal was strong. Fidelity reached 94.4% for lifestyle counseling at the end of study, with 187 of 198 C-QIP participants receiving that counseling component. In implementation terms, the intervention did not collapse under clinic pressure or vanish after enrollment. It stayed visible to patients and staff across months of follow-up.
Acceptability and adoption were central because a quality-improvement strategy can only matter if clinicians and patients will actually use it. The study was built to answer exactly that question before any larger outcomes trial. On those measures, the multicomponent approach proved workable in ordinary outpatient settings, including both public and private hospitals.
The clearest effect appeared in guideline-directed medical therapy for ischemic heart disease and ischemic stroke. Among patients with ischemic heart disease, GDMT use reached 58.3% in the intervention group versus 32.4% with usual care, for a relative risk of 1.45 (95% CI, 1.18 to 1.78). Among patients with ischemic stroke, use rose to 76.7% versus 31.8%, for a relative risk of 2.41 (95% CI, 1.52 to 3.81).
The pattern fits the biology of secondary prevention. After an ischemic event, the main threat is not simply one more clinic visit; it is the cumulative risk of recurrent thrombosis, atherosclerotic progression, and uncontrolled hemodynamic stress. A system that supports prescribing, reinforces adherence, and keeps patients linked to care can alter the medication exposure that suppresses that risk.
Heart failure did not show the same improvement in GDMT within this feasibility cohort. The trial was not powered to sort out whether the issue was phenotype mix, prescribing complexity, baseline practice differences, or the smaller sample available within that subgroup. Even so, the absence of a signal in heart failure is clinically relevant because it suggests the same care model may not transfer evenly across all cardiovascular syndromes.
Adherence gains were broad, not cosmetic
Medication adherence improved alongside prescribing quality. Self-reported adherence to medications was 90.9% in the C-QIP arm versus 82.3% in usual care, with a relative risk of 1.08 (95% CI, 1.04 to 1.12). Diet adherence rose to 91.9% versus 82.3% (RR 1.07, 95% CI, 1.02 to 1.13), and physical activity adherence increased to 91.4% versus 70.4% (RR 1.23, 95% CI, 1.16 to 1.30).
Those changes matter because outpatient cardiovascular prevention depends on repeated behaviors, not a single prescription. When patients receive repeated counseling, reminders, and coordinated follow-up, adherence becomes less dependent on memory, informal family support, or the chance presence of a physician during a crowded clinic day. The intervention appears to have shifted the default from passive follow-up to structured chronic care.
One sentence captures the clinical consequence plainly: the intervention increased the use of preventive therapy where underuse had been the norm.
Why this model fits India’s chronic care gap
The trial sits inside a larger problem of persistent implementation failure in low- and middle-income settings. Background data in the article show how wide the gap remains: in earlier global data, use of recommended secondary-prevention drugs after prior cardiovascular disease was low overall, and the Indian figures were especially discouraging over long-term follow-up. The public health question is not whether the drugs work; it is how to make sure eligible patients actually receive them over time.
C-QIP tries to answer that by combining system, provider, and patient-level levers in one workflow. Electronic decision support helps clinicians identify what is missing. Non-physician care coordination reduces the burden on overextended doctors. Patient education and text reminders address the practical reasons people stop therapy. Audit-feedback closes the loop by making performance visible to clinics rather than leaving it buried in charts.
The design also reflects an important implementation principle: no single fix is likely to close a multifactorial care gap. Fragmented delivery, clinical inertia, limited awareness, and inconsistent follow-up do not yield to one-off training sessions alone. A bundle is more plausible because it attacks the bottlenecks simultaneously.
Feasibility came first, but outcomes questions remain open
This was a feasibility randomized controlled trial, not a definitive outcomes study. The investigators were explicit about the limitations: individual randomization within shared clinics creates contamination risk, the study had limited power for clinical outcomes, and subgroup analyses were underpowered. Those constraints make the findings useful, but not final.
The trial did not establish whether the intervention reduces heart attacks, recurrent strokes, hospitalizations, or mortality. It also did not resolve whether similar gains can be sustained across a larger network of clinics or embedded into the national secondary-prevention infrastructure. What the study does show is that a complex quality-improvement package can be delivered with high retention and strong fidelity in routine Indian outpatient care.
A future hybrid effectiveness-implementation trial will need a cluster-randomized design to reduce spillover between treatment groups and to test whether the gains in prescribing and adherence translate into fewer cardiovascular events. The central unanswered question is not whether the intervention can be built; it is whether it can change hard outcomes when scaled beyond four hospitals and evaluated under the pressures of everyday care.
For now, the evidence points in a narrower direction: chronic cardiovascular prevention in India can be improved when clinics coordinate the work, technology supports the decision, and patients are brought back into the treatment loop instead of being left to navigate it alone.